Elutia INC 10-Q quarterly reports

Elutia Inc. reports Q2 2026 results marked by continued net losses, a potential Nasdaq delisting, and significant litigation expenses, alongside progress in strategic divestitures and new financing.

Elutia Inc. reports a Q3 2025 net loss of $3.9 million, driven by a strategic divestiture of its CIED business, while facing Nasdaq delisting risk and focusing on its drug-eluting biomatrix platform.

Elutia Inc. reported a reduced net loss in Q2 2025, driven by a gain on warrant revaluation and EluPro sales growth, despite overall revenue decline and ongoing litigation costs.

Elutia Inc. reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while focusing on commercializing EluPro and managing legal liabilities.

Elutia Inc.'s third quarter 2024 results show a net income of $1.3 million, driven by a gain on revaluation of warrant liability, despite a slight decrease in net sales compared to the same period last year.

Elutia Inc. reported a net loss of $28.2 million for the second quarter of 2024, alongside ongoing litigation and concerns about its ability to continue as a going concern.

Elutia Inc. reported a net loss of $17.994 million for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.